• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)

PRODUCT FILTERS

REGION

6

CATEGORIES

  • 3
  • 2
  • 2
  • 1
  • 1
  • 1

PRICE

0
0
2
7

PUBLISHED

0
0
0
7

PRODUCT TYPE

6
1

Search "Non-Small Cell Lung Cancer - Avastin to Lead the Market" returned 7 results.

PRODUCT TITLE
AVEO Pharmaceuticals’ and Astellas Pharma’s Tivozanib - Can this angiogenesis inhibitor distinguish itself from the field? AVEO Pharmaceuticals’ and Astellas Pharma’s Tivozanib - Can this angiogenesis inhibitor distinguish itself from the field? - Product Thumbnail Image

AVEO Pharmaceuticals’ and Astellas Pharma’s Tivozanib - Can this angiogenesis inhibitor distinguish itself from the field?

Tivozanib is a small molecule VEGF receptor inhibitor in phase III development for renal cell carcinoma (RCC), developed by AVEO Pharmaceuticals and recently partnered with Astellas Pharma It will not...

July 2011
FROM
Angiogenesis Inhibitors and Stimulators - Global Business Strategic Report Angiogenesis Inhibitors and Stimulators - Global Business Strategic Report - Product Thumbnail Image

Angiogenesis Inhibitors and Stimulators - Global Business Strategic Report

This report analyzes the worldwide markets for Angiogenesis Inhibitors and Stimulators in US$ Million by the following Product Segments: Angiogenesis Inhibitors, and Angiogenesis Stimulators Annual...

May 2012
FROM
Cancer Therapies - Global Strategic Business Report Cancer Therapies - Global Strategic Business Report - Product Thumbnail Image

Cancer Therapies - Global Strategic Business Report

This report analyzes the worldwide markets for Cancer Therapies in US$ Million by the following Product Segments: Immunotherapy, Targeted Therapy, Hormonal Therapy, and Chemotherapy The report provides...

October 2011
FROM
Chemotherapy Market Insights, 2006-2016: A Critical Analysis of Cancer Research, Treatments, Pipelines, and Commercial Opportunities Chemotherapy Market Insights, 2006-2016: A Critical Analysis of Cancer Research, Treatments, Pipelines, and Commercial Opportunities - Product Thumbnail Image

Chemotherapy Market Insights, 2006-2016: A Critical Analysis of Cancer Research, Treatments, Pipelines, and Commercial Opportunities

In a market currently valued around US$42 billion, cancer chemotherapies are on course for staggering growth potential and may revolutionize cancer treatments over the next 10 years according to a new...

April 2006
FROM
Preclinical Cancer Therapeutics 2007: Decoding Next Generation Drug Targets for Market Success Preclinical Cancer Therapeutics 2007: Decoding Next Generation Drug Targets for Market Success - Product Thumbnail Image

Preclinical Cancer Therapeutics 2007: Decoding Next Generation Drug Targets for Market Success

This is a unique and unrivalled 367-page report analysing the performance of numerous important early stage oncology drug candidates, assessing their market viability based on preclinical scientific...

November 2006
FROM

PharmaPoint: Non-Small Cell Lung Cancer - Global Drug Forecast and Market Analysis to 2022

PharmaPoint: Non-Small Cell Lung Cancer - Global Drug Forecast and Market Analysis to 2022 Summary Non-Small Cell Lung Cancer (NSCLC) is the most common lung cancer, and the second-most common cancer...

June 2013
FROM
Idera Pharmaceuticals, Inc. - Product Pipeline Review - 2012 Idera Pharmaceuticals, Inc. - Product Pipeline Review - 2012 - Product Thumbnail Image

Idera Pharmaceuticals, Inc. - Product Pipeline Review - 2012

Idera Pharmaceuticals, Inc. – Product Pipeline Review – 2012 Summary Global Markets Direct’s pharmaceuticals report, “Idera Pharmaceuticals, Inc. - Product Pipeline Review - 2012” provides data on...

August 2012
FROM
Loading Indicator